Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Axiom Group
San Francisco, California, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
Axiom Bio's AI model identifies toxic compounds with 70–75% sensitivity and 90% accuracy in identifying safe compounds, matching or exceeding lab-based assays at $100–$450 per compound versus $3,000–$15,000 for physical experiments[1]. The model has demonstrated predictive performance in clinical trials including risk identification for Lotiglipron and Danuglipron programs[1].
- Therapeutic areas
- Other
- Modalities
- Small molecule prediction (AI-based)
- Industry
- Drug Discovery Services
02
Partnerships
Six of the top twenty pharmaceutical companiesmajor agrochemical companymultiple hedge fundsseveral biotechnology firms
Beyond the preview
Go deeper on Axiom Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axiom Group.